. Author manuscript; available in PMC: 2021 Jun 1.

Published in final edited form as: Gynecol Oncol. 2020 Apr 4;157(3):783–792. doi: 10.1016/j.ygyno.2020.03.026

Table 2.

Clinicodemographics of participants.

Participant	Specimen	Race/ethnicity	Age	Source	Stage/histology^a	Prior treatment	Days from last infusion

1	OV469	White/non-Hispanic	56	Ascites	IIIC HGS Peritoneal cancer	Untreated	NA
2	OV778	White/non-Hispanic	74	Ascites	IVB HGSOC	Untreated	NA
3^b	OV798 OV817 OV820 OV838 OV840	White/non-Hispanic	61	Pleural effusion	IIIC HGSOC	C1 paclitaxel/bevacizumab C4 paclitaxel/bevacizumab C5 paclitaxel/bevacizumab C6 paclitaxel/bevacizumab C1 gemcitabine	21 14 7 14 2
4	OV899 OV860	White/non-Hispanic	74	Ascites	IIIC HGSOC	Untreated C1 carboplatin/paclitaxel	NA 4
5	OV867 OV875 OV882	White/non-Hispanic	62	Ascites Ascites Ascites	IVB HGSOC	C1 carboplatin/paclitaxel C1 carboplatin/doxorubicin C1 carboplatin/doxorubicin	3
6^c	OV870 OV888	White/non-Hispanic	54	Ascites Ascites	IIIC HGSOC	See footnote	46

C = Cycle; HGS = High grade serous; HGSOC = High grade serous ovarian cancer.

Stage at time of original diagnosis.

Prior to first specimen, patient underwent treatment with AZD2014, bevacizumab, carboplatin, cisplatin, doxorubicin, olaparib, paclitaxel, topotecan, in combination or as a single agent.

Prior to first specimen, patient underwent treatment with ABT888 (PARP inhibitor), bevacizumab, carboplatin, pegylated liposomal doxorubicin, paclitaxel, topotecan. Prior to collection of OV888, patient initiated therapy with anastrazole.